232 related articles for article (PubMed ID: 27559096)
21. [Bone hyperresorption in neoplastic diseases. Foreword].
Vinceneux P
Presse Med; 2000 Mar; 29(9):485-6. PubMed ID: 10745941
[No Abstract] [Full Text] [Related]
22. Runx2 Suppression by miR-342 and miR-363 Inhibits Multiple Myeloma Progression.
Gowda PS; Wildman BJ; Trotter TN; Xu X; Hao X; Hassan MQ; Yang Y
Mol Cancer Res; 2018 Jul; 16(7):1138-1148. PubMed ID: 29592898
[TBL] [Abstract][Full Text] [Related]
23. Update on the pathogenesis of osteolysis in multiple myeloma patients.
Giuliani N; Colla S; Rizzoli V
Acta Biomed; 2004 Dec; 75(3):143-52. PubMed ID: 15796087
[TBL] [Abstract][Full Text] [Related]
24. The critical role of interleukin-6, interleukin-1B and macrophage colony-stimulating factor in the pathogenesis of bone lesions in multiple myeloma.
Bataille R; Chappard D; Klein B
Int J Clin Lab Res; 1992; 21(4):283-7. PubMed ID: 1591381
[TBL] [Abstract][Full Text] [Related]
25. [Bone disease in multiple myeloma and its mechanism].
Abe M
Clin Calcium; 2006 Apr; 16(4):565- 71. PubMed ID: 16582506
[TBL] [Abstract][Full Text] [Related]
26. [Pathophysiology of bone metastases in urologic carcinomas].
Sauer G; Barth TF; Möller P
Urologe A; 2007 Aug; 46(8):888-90. PubMed ID: 17632696
[TBL] [Abstract][Full Text] [Related]
27. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.
Heath DJ; Chantry AD; Buckle CH; Coulton L; Shaughnessy JD; Evans HR; Snowden JA; Stover DR; Vanderkerken K; Croucher PI
J Bone Miner Res; 2009 Mar; 24(3):425-36. PubMed ID: 19016584
[TBL] [Abstract][Full Text] [Related]
28. Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma.
Breitkreutz I; Raab MS; Vallet S; Hideshima T; Raje N; Chauhan D; Munshi NC; Richardson PG; Anderson KC
Br J Haematol; 2007 Oct; 139(1):55-63. PubMed ID: 17854307
[TBL] [Abstract][Full Text] [Related]
29. [Bone hyperresorption in bone metastases].
Clézardin P
Presse Med; 2000 Mar; 29(9):487-91. PubMed ID: 10745942
[TBL] [Abstract][Full Text] [Related]
30. Osteoblast function in myeloma.
Roodman GD
Bone; 2011 Jan; 48(1):135-40. PubMed ID: 20601285
[TBL] [Abstract][Full Text] [Related]
31. Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation.
Boissy P; Andersen TL; Abdallah BM; Kassem M; Plesner T; Delaissé JM
Cancer Res; 2005 Nov; 65(21):9943-52. PubMed ID: 16267019
[TBL] [Abstract][Full Text] [Related]
32. Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease.
Liu H; He J; Koh SP; Zhong Y; Liu Z; Wang Z; Zhang Y; Li Z; Tam BT; Lin P; Xiao M; Young KH; Amini B; Starbuck MW; Lee HC; Navone NM; Davis RE; Tong Q; Bergsagel PL; Hou J; Yi Q; Orlowski RZ; Gagel RF; Yang J
Sci Transl Med; 2019 May; 11(494):. PubMed ID: 31142679
[TBL] [Abstract][Full Text] [Related]
33. Bone-resorbing cells in multiple myeloma: osteoclasts, myeloma cell polykaryons, or both?
Silvestris F; Ciavarella S; De Matteo M; Tucci M; Dammacco F
Oncologist; 2009 Mar; 14(3):264-75. PubMed ID: 19286760
[TBL] [Abstract][Full Text] [Related]
34. Myeloma cell-derived Runx2 promotes myeloma progression in bone.
Trotter TN; Li M; Pan Q; Peker D; Rowan PD; Li J; Zhan F; Suva LJ; Javed A; Yang Y
Blood; 2015 Jun; 125(23):3598-608. PubMed ID: 25862559
[TBL] [Abstract][Full Text] [Related]
35. Bone loss induced by Runx2 over-expression in mice is blunted by osteoblastic over-expression of TIMP-1.
Schiltz C; Prouillet C; Marty C; Merciris D; Collet C; de Vernejoul MC; Geoffroy V
J Cell Physiol; 2010 Jan; 222(1):219-29. PubMed ID: 19780057
[TBL] [Abstract][Full Text] [Related]
36. Human placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in bone.
Li X; Ling W; Pennisi A; Wang Y; Khan S; Heidaran M; Pal A; Zhang X; He S; Zeitlin A; Abbot S; Faleck H; Hariri R; Shaughnessy JD; van Rhee F; Nair B; Barlogie B; Epstein J; Yaccoby S
Stem Cells; 2011 Feb; 29(2):263-73. PubMed ID: 21732484
[TBL] [Abstract][Full Text] [Related]
37. Multiple Myeloma and Bone: The Fatal Interaction.
Marino S; Roodman GD
Cold Spring Harb Perspect Med; 2018 Aug; 8(8):. PubMed ID: 29229668
[TBL] [Abstract][Full Text] [Related]
38. MiR-30a inhibits osteolysis by targeting RunX2 in giant cell tumor of bone.
Huang Q; Jiang Z; Meng T; Yin H; Wang J; Wan W; Cheng M; Yan W; Liu T; Song D; Chen H; Wu Z; Xu W; Li Z; Zhou W; Xiao J
Biochem Biophys Res Commun; 2014 Oct; 453(1):160-5. PubMed ID: 25264196
[TBL] [Abstract][Full Text] [Related]
39. Coenzyme q10 regulates osteoclast and osteoblast differentiation.
Moon HJ; Ko WK; Jung MS; Kim JH; Lee WJ; Park KS; Heo JK; Bang JB; Kwon IK
J Food Sci; 2013 May; 78(5):H785-891. PubMed ID: 23582186
[TBL] [Abstract][Full Text] [Related]
40. The Transcriptional Modulator Interferon-Related Developmental Regulator 1 in Osteoblasts Suppresses Bone Formation and Promotes Bone Resorption.
Iezaki T; Onishi Y; Ozaki K; Fukasawa K; Takahata Y; Nakamura Y; Fujikawa K; Takarada T; Yoneda Y; Yamashita Y; Shioi G; Hinoi E
J Bone Miner Res; 2016 Mar; 31(3):573-84. PubMed ID: 26391411
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
